AKYA vs. ATHA, PRLD, NAUT, HBIO, SEER, BNGO, PRE, RPID, AXDX, and OMIC
Should you be buying Akoya Biosciences stock or one of its competitors? The main competitors of Akoya Biosciences include Athira Pharma (ATHA), Prelude Therapeutics (PRLD), Nautilus Biotechnology (NAUT), Harvard Bioscience (HBIO), Seer (SEER), Bionano Genomics (BNGO), Prenetics Global (PRE), Rapid Micro Biosystems (RPID), Accelerate Diagnostics (AXDX), and Singular Genomics Systems (OMIC).
Athira Pharma (NASDAQ:ATHA) and Akoya Biosciences (NASDAQ:AKYA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, community ranking, media sentiment, profitability, analyst recommendations, risk and valuation.
Akoya Biosciences received 10 more outperform votes than Athira Pharma when rated by MarketBeat users. Likewise, 60.87% of users gave Akoya Biosciences an outperform vote while only 58.06% of users gave Athira Pharma an outperform vote.
57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 79.4% of Akoya Biosciences shares are owned by institutional investors. 19.8% of Athira Pharma shares are owned by insiders. Comparatively, 7.3% of Akoya Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Athira Pharma had 1 more articles in the media than Akoya Biosciences. MarketBeat recorded 4 mentions for Athira Pharma and 3 mentions for Akoya Biosciences. Akoya Biosciences' average media sentiment score of 1.55 beat Athira Pharma's score of 0.82 indicating that Athira Pharma is being referred to more favorably in the media.
Athira Pharma currently has a consensus price target of $19.00, suggesting a potential upside of 642.19%. Akoya Biosciences has a consensus price target of $7.79, suggesting a potential upside of 238.51%. Given Akoya Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Athira Pharma is more favorable than Akoya Biosciences.
Akoya Biosciences has higher revenue and earnings than Athira Pharma. Akoya Biosciences is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.
Athira Pharma has a beta of 2.83, indicating that its share price is 183% more volatile than the S&P 500. Comparatively, Akoya Biosciences has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.
Athira Pharma has a net margin of 0.00% compared to Athira Pharma's net margin of -72.68%. Akoya Biosciences' return on equity of -80.59% beat Athira Pharma's return on equity.
Summary
Athira Pharma beats Akoya Biosciences on 9 of the 17 factors compared between the two stocks.
Get Akoya Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKYA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akoya Biosciences Competitors List
Related Companies and Tools
